« Return to News | CROs/Service Providers

Genstar Capital completes ERT acquisition

Thursday, July 5, 2012 09:12 AM

Genstar Capital, a private equity firm, has completed its acquisition of ERT, a global technology-driven provider of health outcomes, in a take-private transaction valued at approximately $400 million.

“As a private company we will continue to serve our customers and enhance our suite of products,” Dr. Jeffrey Litwin, who will continue to lead ERT as CEO, said. “We have been able to grow our company into a global leader, and, with Genstar’s partnership, we will look for creative new ways to grow our business organically and identify new investment opportunities as part of our continued development.”

Robert Weltman, managing director of Genstar, said, “ERT is already the global leader in its sector, yet we believe the company can benefit from our expertise in the pharmaceuticals industry to create positive change that will drive operations at an increased pace. This is a sector we know well, and the added strength of our operating partners and strategic advisory board will help build ERT into a stronger independent platform company.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.